Cyteir to dis­solve as on­col­o­gy biotech scraps its fi­nal clin­i­cal at­tempt two years af­ter IPO

Cyteir Ther­a­peu­tics will dis­solve, liq­ui­date and re­turn re­main­ing cash to share­hold­ers, the Lex­ing­ton, MA-based biotech said Fri­day morn­ing.

The pub­lic com­pa­ny …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER